TheraRadar
Clinical-Stage Companies / Intellia

Intellia

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 1/15/2025

7
Total Trials
3
Phase 3
3
Phase 2
4
Recruiting
81
Score

Pipeline by Phase

Phase 3
3
Phase 2
3
Phase 1
4

Therapeutic Focus

Hereditary Angioedema Neuromuscular Disease Neuromuscular Diseases (NMD) Neurodegenerative Disease Neurodegenerative Disease, Hereditary

Clinical Trials (7)

NCT06672237 Phase 3 RECRUITING

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Started: 11/22/2024

NCT06128629 Phase 3 RECRUITING

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Started: 12/13/2023

NCT06634420 Phase 3 ACTIVE NOT RECRUITING

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Started: 1/15/2025

NCT05120830 Phase 1 ACTIVE NOT RECRUITING

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Started: 12/10/2021

NCT04601051 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Started: 11/5/2020

NCT06622668 Phase 1 WITHDRAWN

NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

Started: 11/20/2024

NCT05066165 Phase 1 TERMINATED

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Started: 12/17/2021

Drug Candidates

nexiguran ziclumeran Normal Saline as Placebo NTLA-2001 Placebo Biological NTLA-2002 NTLA-2002 Normal Saline IV Administration Biological NTLA-3001
Activity Status: Slowing
Last Trial Started: 1/15/2025
Last Trial Ended: 9/12/2025
Trials (12 months): 0
Completed Trials: 1
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.